Debt-to-EBITDA measures a company's ability to pay off its debt.
Medtronic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2022 was $3,742 Mil. Medtronic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2022 was $20,372 Mil. Medtronic's annualized EBITDA for the quarter that ended in Apr. 2022 was $9,732 Mil.
Medtronic's annualized Debt-to-EBITDA for the quarter that ended in Apr. 2022 was 2.48.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medtronic's Debt-to-EBITDA or its related term are showing as below:
MDT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.94 Med: 2.96 Max: 6.62
Current: 2.75
During the past 13 years, the highest Debt-to-EBITDA Ratio of Medtronic was 6.62. The lowest was 1.94. And the median was 2.96.
MDT's Debt-to-EBITDA is ranked worse than 73.91% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 1.09
vs MDT: 2.75
Medtronic Debt-to-EBITDA Historical Data
The historical data trend for Medtronic's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Medtronic Annual Data
Trend
Apr13
Apr14
Apr15
Apr16
Apr17
Apr18
Apr19
Apr20
Apr21
Apr22
Debt-to-EBITDA
2.72
2.72
3.18
3.51
2.75
Medtronic Quarterly Data
Jul17
Oct17
Jan18
Apr18
Jul18
Oct18
Jan19
Apr19
Jul19
Oct19
Jan20
Apr20
Jul20
Oct20
Jan21
Apr21
Jul21
Oct21
Jan22
Apr22
Debt-to-EBITDA
2.76
3.96
2.78
2.62
2.48
Competitive Comparison
For the Medical Devices subindustry, Medtronic's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtronic Debt-to-EBITDA Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medtronic's Debt-to-EBITDA falls into.
Medtronic Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Medtronic's Debt-to-EBITDA for the fiscal year that ended in Apr. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2022) EBITDA data.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medtronic Debt-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Medtronic's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.48(0.51%) Volume: 2,941,396 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MDT has been successfully added to your 
